|

Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

RECRUITINGN/ASponsored by Massachusetts General Hospital
Actively Recruiting
PhaseN/A
SponsorMassachusetts General Hospital
Started2025-10-15
Est. completion2026-10-15
Eligibility
Age30 Years – 75 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07087431

Summary

The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.

Eligibility

Age: 30 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Current age 30-75 years
* Established primary care at Mass General Brigham with at least one visit in the last 2 years

Exclusion Criteria:

\- Currently taking LDL cholesterol- lowering medications, including statins

Conditions2

Coronary Artery DiseaseHeart Disease

Locations1 site

Massachusetts General Hospital
Boston, Massachusetts, 02114
Akl Fahed, MD, MPH6176434842afahed@mgh.harvard.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.